Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3171647 | 0.99 | KCNJ1 (0.58) | KCNJ1ALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL2073757 | 0.89 | KCNJ1 (0.57) | KCNJ1ALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL4269241 | 0.88 | KCNJ1 (0.74) | KCNJ1ALDH1A1HTTKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7564284 | 0.88 | KCNJ1 (0.58) | KCNJ1ALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL14386708 | 0.86 | KMT2A (0.52) | KCNJ1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5388591 | 0.84 | ALDH1A1 (0.54) | KCNJ1ALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL21412829 | 0.84 | CA12 (0.56) | KCNJ1ALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL9609632 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL11192692 | 0.81 | LMNA (0.56) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL4162538 | 0.79 | HTT (0.64) | ALDH1A1HTTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-7981880-B2 | 3-(aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090105216-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008152013-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007122219-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATIVES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-01 | — | — | WO | disclosed |
| EP-0997460-B1 | Benzothiophene compounds as antithrombotic agents and intermediates | LILLY CO ELI (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6133262-A | 3-AMINOBENZO(B)THIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0997460-A1 | Benzothiophene compounds as antithrombotic agents and intermediates | ELI LILLY AND COMPANY (US) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | KCNJ1 2849/4885ALDH1A1 243/4885HTT 706/4885 |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | KCNJ1 2849/4885ALDH1A1 243/4885HTT 706/4885 |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | KCNJ1 2565/4885ALDH1A1 668/4885HTT 181/4885 |
| US-20090105216-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | MKI67, CCNI, CCNA1 | KCNJ1 2421/4885ALDH1A1 170/4885HTT 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.